Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapyElisabetta Signoriello, Alessio Signori, Francesco Saccà et al.|Multiple Sclerosis Journal|2021Cited by 19
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Daniela Cargnelutti, Federica Matrone et al.|Journal of Neurology|2023Cited by 12